The best way to Alprolix.com Login. Here are the most relevant links that help you to Alprolix.com Login.

ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion ...

    https://www.alprolix.com/index
    Learn about ALPROLIX, a therapy regimen for the treatment of hemophilia B that uses Fc Fusion to keep Factor IX circulating in your bloodstream longer

Alprolix Labeling Updated With Long-Term Data, Additional ...

    https://www.empr.com/home/news/alprolix-labeling-updated-with-long-term-data-additional-adverse-reaction/
    Nov 27, 2017 · Login Register. Home » News. Publish Date November 27, ... For more information call (855) 692-5776 or visit Alprolix.com. Topics: Bleeding Disorders Hematologic Disorders Pediatrics. Recommended ...

UpToDate

    https://www.uptodate.com/contents/hemophilia-a-and-b-routine-management-including-prophylaxis?search=hemophilia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
    {{configCtrl2.info.metaDescription}} INTRODUCTION. Hemophilia A (factor VIII [factor 8] deficiency) and hemophilia B (factor IX [factor 9] deficiency) are X-linked inherited coagulation factor deficiencies that result in lifelong bleeding disorders.

Albutrepenonacog alfa (Idelvion®) for the treatment of ...

    https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1328/www.alprolix.com/pdfs/PrescribingInformation.pdf
    BACKGROUND: Enhanced pharmacokinetic profile of albutrepenonacog alfa allows to prolong the interdose period in prophylaxis, maintaining higher trough …Cited by: 1

Biogen Idec (BIIB) Reports FDA Approval of ALPROLIX

    https://www.streetinsider.com/Corporate+News/Biogen+Idec+%28BIIB%29+Reports+FDA+Approval+of+ALPROLIX/9330728.html
    Biogen Idec (BIIB) Reports FDA Approval of ALPROLIX Article Related Press Releases ( 2 ) Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider.com!

Efficacy and safety of long‐acting recombinant fusion ...

    https://onlinelibrary.wiley.com/doi/full/10.1111/hae.12972
    Jun 22, 2016 · Login / Register. Haemophilia. Volume 22, Issue 4. Original Article. Open Access. Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. C. Négrier. Corresponding Author.Cited by: 8

Albutrepenonacog alfa (Idelvion®) for the treatment of ...

    https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1328/1682
    Population. Target population is defined based on 2014 data of NRCC [2], which collects epidemiological and therapeutic data from 54 Hemophilia Treatment Centers and reports a …Cited by: 1

FDA Approves New Bleeding Prophylactic for Hemophilia B ...

    https://www.empr.com/home/news/fda-approves-new-bleeding-prophylactic-for-hemophilia-b-patients/
    Mar 31, 2014 · The FDA has approved Alprolix injection to help control and prevent bleeding episodes, manage bleeding during surgical procedures, and prevent or reduce the frequency of …

(PDF) Long-acting recombinant coagulation factor IX ...

    https://www.researchgate.net/publication/290221528_Long-acting_recombinant_coagulation_factor_IX_albumin_fusion_protein_rIX-FP_in_hemophilia_B_Results_of_a_phase_3_trial
    Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: Results of a phase 3 trial

Specialty Drugs: Year in Review 2014 - Pharmacy Times

    https://www.pharmacytimes.com/publications/specialty-pharmacy-times/2015/february-2015/specialty-drugs-year-in-review-2014
    About the Author Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, has worked in both national specialty pharmacy and payer organizations and has experience in clinical management, adherence and persistency programs, as well as chronic disease cost optimization strategies.Dr. Ness is active in the Consortium of Multiple Sclerosis Centers, Academy of Managed Care Pharmacy, National Home …

Related Login Pages